Information Provided By: 
Fly News Breaks for February 21, 2019
PTGX
Feb 21, 2019 | 17:20 EDT
BMO Capital analyst George Farmer initiated Protagonist Therapeutics with an Outperform rating and $17 price target. Farmer said the recent stock pullback offers an attractive entry point based on the potential of the company's "novel peptide chemistry platform," and that positive outcomes of upcoming catalysts this year could drive shares close to $17 per share.
News For PTGX From the Last 2 Days
There are no results for your query PTGX
